nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB4—amyotrophic lateral sclerosis	0.583	1	CbGaD
Afatinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.258	1	CbGbCtD
Afatinib—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.00371	0.102	CcSEcCtD
Afatinib—PHKG2—hindbrain—amyotrophic lateral sclerosis	0.00334	0.073	CbGeAlD
Afatinib—DYRK1A—hindbrain—amyotrophic lateral sclerosis	0.00289	0.0632	CbGeAlD
Afatinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0614	CcSEcCtD
Afatinib—PHKG2—brainstem—amyotrophic lateral sclerosis	0.00191	0.0419	CbGeAlD
Afatinib—ERBB2—embryo—amyotrophic lateral sclerosis	0.00188	0.0411	CbGeAlD
Afatinib—ERBB4—embryo—amyotrophic lateral sclerosis	0.00188	0.0411	CbGeAlD
Afatinib—ERBB4—brainstem—amyotrophic lateral sclerosis	0.00172	0.0376	CbGeAlD
Afatinib—DYRK1A—brainstem—amyotrophic lateral sclerosis	0.00165	0.0362	CbGeAlD
Afatinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00137	0.0377	CcSEcCtD
Afatinib—PHKG2—medulla oblongata—amyotrophic lateral sclerosis	0.00133	0.0292	CbGeAlD
Afatinib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.00126	0.0275	CbGeAlD
Afatinib—ERBB4—medulla oblongata—amyotrophic lateral sclerosis	0.0012	0.0262	CbGeAlD
Afatinib—Vandetanib—VEGFA—amyotrophic lateral sclerosis	0.00113	1	CrCbGaD
Afatinib—ERBB4—spinal cord—amyotrophic lateral sclerosis	0.00107	0.0234	CbGeAlD
Afatinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0293	CcSEcCtD
Afatinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0287	CcSEcCtD
Afatinib—EPHA6—nervous system—amyotrophic lateral sclerosis	0.00104	0.0227	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00103	0.0284	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0278	CcSEcCtD
Afatinib—HIPK4—brain—amyotrophic lateral sclerosis	0.001	0.022	CbGeAlD
Afatinib—PHKG2—nervous system—amyotrophic lateral sclerosis	0.001	0.0219	CbGeAlD
Afatinib—EPHA6—central nervous system—amyotrophic lateral sclerosis	0.001	0.0219	CbGeAlD
Afatinib—PHKG2—central nervous system—amyotrophic lateral sclerosis	0.000965	0.0211	CbGeAlD
Afatinib—PHKG2—cerebellum—amyotrophic lateral sclerosis	0.000943	0.0206	CbGeAlD
Afatinib—ERBB2—nervous system—amyotrophic lateral sclerosis	0.000901	0.0197	CbGeAlD
Afatinib—ERBB4—nervous system—amyotrophic lateral sclerosis	0.000901	0.0197	CbGeAlD
Afatinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000896	0.0247	CcSEcCtD
Afatinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000888	0.0244	CcSEcCtD
Afatinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000883	0.0243	CcSEcCtD
Afatinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000883	0.0243	CcSEcCtD
Afatinib—ERBB2—central nervous system—amyotrophic lateral sclerosis	0.000867	0.019	CbGeAlD
Afatinib—ERBB4—central nervous system—amyotrophic lateral sclerosis	0.000867	0.019	CbGeAlD
Afatinib—DYRK1A—nervous system—amyotrophic lateral sclerosis	0.000867	0.019	CbGeAlD
Afatinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000861	0.0237	CcSEcCtD
Afatinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000858	0.0236	CcSEcCtD
Afatinib—ERBB2—cerebellum—amyotrophic lateral sclerosis	0.000848	0.0186	CbGeAlD
Afatinib—ERBB4—cerebellum—amyotrophic lateral sclerosis	0.000848	0.0186	CbGeAlD
Afatinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000835	0.023	CcSEcCtD
Afatinib—DYRK1A—central nervous system—amyotrophic lateral sclerosis	0.000835	0.0183	CbGeAlD
Afatinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000833	0.0229	CcSEcCtD
Afatinib—DYRK1A—cerebellum—amyotrophic lateral sclerosis	0.000816	0.0179	CbGeAlD
Afatinib—EPHA6—brain—amyotrophic lateral sclerosis	0.000794	0.0174	CbGeAlD
Afatinib—ABL1—embryo—amyotrophic lateral sclerosis	0.000786	0.0172	CbGeAlD
Afatinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000783	0.0215	CcSEcCtD
Afatinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000779	0.0214	CcSEcCtD
Afatinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000777	0.0214	CcSEcCtD
Afatinib—PHKG2—brain—amyotrophic lateral sclerosis	0.000766	0.0168	CbGeAlD
Afatinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000741	0.0204	CcSEcCtD
Afatinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.00072	0.0158	CbGeAlD
Afatinib—EGFR—cerebellum—amyotrophic lateral sclerosis	0.000719	0.0157	CbGeAlD
Afatinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000714	0.0197	CcSEcCtD
Afatinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.0007	0.0193	CcSEcCtD
Afatinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000694	0.0191	CcSEcCtD
Afatinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00069	0.019	CcSEcCtD
Afatinib—ERBB4—brain—amyotrophic lateral sclerosis	0.000689	0.0151	CbGeAlD
Afatinib—ERBB2—brain—amyotrophic lateral sclerosis	0.000689	0.0151	CbGeAlD
Afatinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000676	0.0186	CcSEcCtD
Afatinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000667	0.0184	CcSEcCtD
Afatinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000663	0.0183	CcSEcCtD
Afatinib—DYRK1A—brain—amyotrophic lateral sclerosis	0.000663	0.0145	CbGeAlD
Afatinib—IRAK1—cerebellum—amyotrophic lateral sclerosis	0.000634	0.0139	CbGeAlD
Afatinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.000602	0.0166	CcSEcCtD
Afatinib—EGFR—brain—amyotrophic lateral sclerosis	0.000584	0.0128	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000583	0.0161	CcSEcCtD
Afatinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.000559	0.0154	CcSEcCtD
Afatinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000552	0.0152	CcSEcCtD
Afatinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000547	0.0151	CcSEcCtD
Afatinib—IRAK1—brain—amyotrophic lateral sclerosis	0.000515	0.0113	CbGeAlD
Afatinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000509	0.014	CcSEcCtD
Afatinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000502	0.011	CbGeAlD
Afatinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000502	0.0138	CcSEcCtD
Afatinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000496	0.0136	CcSEcCtD
Afatinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000489	0.0135	CcSEcCtD
Afatinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000486	0.0134	CcSEcCtD
Afatinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000485	0.0134	CcSEcCtD
Afatinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000482	0.0133	CcSEcCtD
Afatinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000448	0.0098	CbGeAlD
Afatinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000445	0.0123	CcSEcCtD
Afatinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000404	0.0111	CcSEcCtD
Afatinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000398	0.011	CcSEcCtD
Afatinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000385	0.0106	CcSEcCtD
Afatinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000377	0.00826	CbGeAlD
Afatinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000372	0.0102	CcSEcCtD
Afatinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000363	0.00795	CbGeAlD
Afatinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000358	0.00985	CcSEcCtD
Afatinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000355	0.00777	CbGeAlD
Afatinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00977	CcSEcCtD
Afatinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00976	CcSEcCtD
Afatinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000353	0.00971	CcSEcCtD
Afatinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000334	0.0092	CcSEcCtD
Afatinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000317	0.00693	CbGeAlD
Afatinib—ABL1—brain—amyotrophic lateral sclerosis	0.000288	0.00631	CbGeAlD
Afatinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000282	0.00618	CbGeAlD
Afatinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000244	0.00535	CbGeAlD
Afatinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000224	0.0049	CbGeAlD
Afatinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000182	0.00398	CbGeAlD
Afatinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000156	0.00342	CbGeAlD
Afatinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000139	0.00305	CbGeAlD
Afatinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000117	0.00257	CbGeAlD
Afatinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000113	0.00247	CbGeAlD
Afatinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.00011	0.00242	CbGeAlD
Afatinib—ABCB1—brain—amyotrophic lateral sclerosis	8.97e-05	0.00196	CbGeAlD
Afatinib—PHKG2—Metabolism—APOE—amyotrophic lateral sclerosis	3.41e-05	0.000453	CbGpPWpGaD
Afatinib—LCK—Disease—CHMP2B—amyotrophic lateral sclerosis	3.38e-05	0.000448	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.38e-05	0.000448	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—ATF1—amyotrophic lateral sclerosis	3.37e-05	0.000447	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	3.37e-05	0.000447	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	3.35e-05	0.000445	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.35e-05	0.000445	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.32e-05	0.000441	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CASP9—amyotrophic lateral sclerosis	3.31e-05	0.000438	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—amyotrophic lateral sclerosis	3.29e-05	0.000436	CbGpPWpGaD
Afatinib—BLK—Immune System—ATF1—amyotrophic lateral sclerosis	3.29e-05	0.000436	CbGpPWpGaD
Afatinib—ABL1—Immune System—DCTN1—amyotrophic lateral sclerosis	3.28e-05	0.000435	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.28e-05	0.000434	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	3.27e-05	0.000434	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CASP9—amyotrophic lateral sclerosis	3.26e-05	0.000432	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	3.25e-05	0.000431	CbGpPWpGaD
Afatinib—DYRK1A—Cell Cycle—TP53—amyotrophic lateral sclerosis	3.24e-05	0.00043	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.22e-05	0.000427	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CASP9—amyotrophic lateral sclerosis	3.21e-05	0.000426	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—SOD1—amyotrophic lateral sclerosis	3.2e-05	0.000424	CbGpPWpGaD
Afatinib—EGFR—Disease—PLB1—amyotrophic lateral sclerosis	3.17e-05	0.000421	CbGpPWpGaD
Afatinib—BLK—Immune System—CASP9—amyotrophic lateral sclerosis	3.13e-05	0.000415	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.12e-05	0.000414	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	3.12e-05	0.000413	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.1e-05	0.000412	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	3.1e-05	0.000411	CbGpPWpGaD
Afatinib—LCK—Disease—PLB1—amyotrophic lateral sclerosis	3.06e-05	0.000405	CbGpPWpGaD
Afatinib—ERBB2—Disease—CASP9—amyotrophic lateral sclerosis	3.05e-05	0.000405	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	3.03e-05	0.000402	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	3.02e-05	0.0004	CbGpPWpGaD
Afatinib—ERBB4—Disease—CASP9—amyotrophic lateral sclerosis	3.01e-05	0.000399	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.96e-05	0.000393	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—C3—amyotrophic lateral sclerosis	2.92e-05	0.000387	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ATF1—amyotrophic lateral sclerosis	2.88e-05	0.000382	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.87e-05	0.000381	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.87e-05	0.00038	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.87e-05	0.00038	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	2.86e-05	0.00038	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	2.85e-05	0.000378	CbGpPWpGaD
Afatinib—ERBB2—Immune System—ERBB4—amyotrophic lateral sclerosis	2.83e-05	0.000375	CbGpPWpGaD
Afatinib—EGFR—Disease—VCP—amyotrophic lateral sclerosis	2.83e-05	0.000375	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	2.83e-05	0.000375	CbGpPWpGaD
Afatinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	2.81e-05	0.000372	CbGpPWpGaD
Afatinib—EGFR—Immune System—DCTN1—amyotrophic lateral sclerosis	2.8e-05	0.000371	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.8e-05	0.000371	CbGpPWpGaD
Afatinib—PHKG2—Disease—PTGS2—amyotrophic lateral sclerosis	2.79e-05	0.00037	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.78e-05	0.000369	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ATF1—amyotrophic lateral sclerosis	2.78e-05	0.000368	CbGpPWpGaD
Afatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—amyotrophic lateral sclerosis	2.76e-05	0.000365	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	2.75e-05	0.000364	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CASP9—amyotrophic lateral sclerosis	2.74e-05	0.000364	CbGpPWpGaD
Afatinib—LCK—Disease—VCP—amyotrophic lateral sclerosis	2.73e-05	0.000361	CbGpPWpGaD
Afatinib—LCK—Immune System—DCTN1—amyotrophic lateral sclerosis	2.7e-05	0.000358	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	2.7e-05	0.000358	CbGpPWpGaD
Afatinib—BLK—Immune System—ERBB4—amyotrophic lateral sclerosis	2.68e-05	0.000356	CbGpPWpGaD
Afatinib—IRAK1—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.68e-05	0.000355	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD40LG—amyotrophic lateral sclerosis	2.66e-05	0.000353	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CASP9—amyotrophic lateral sclerosis	2.64e-05	0.000351	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	2.64e-05	0.00035	CbGpPWpGaD
Afatinib—LCK—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.64e-05	0.000349	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	2.64e-05	0.000349	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD40LG—amyotrophic lateral sclerosis	2.62e-05	0.000348	CbGpPWpGaD
Afatinib—ERBB2—Disease—ERBB4—amyotrophic lateral sclerosis	2.61e-05	0.000346	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.56e-05	0.000339	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	2.55e-05	0.000338	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.55e-05	0.000338	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	2.54e-05	0.000337	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.53e-05	0.000336	CbGpPWpGaD
Afatinib—BLK—Immune System—CD40LG—amyotrophic lateral sclerosis	2.52e-05	0.000334	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.52e-05	0.000334	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ATF1—amyotrophic lateral sclerosis	2.51e-05	0.000333	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.48e-05	0.000329	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.45e-05	0.000325	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.45e-05	0.000325	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	2.43e-05	0.000322	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.39e-05	0.000317	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CASP9—amyotrophic lateral sclerosis	2.39e-05	0.000317	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	2.39e-05	0.000316	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.38e-05	0.000315	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	2.36e-05	0.000313	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.36e-05	0.000313	CbGpPWpGaD
Afatinib—ERBB2—Immune System—C3—amyotrophic lateral sclerosis	2.35e-05	0.000312	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	2.35e-05	0.000311	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.34e-05	0.00031	CbGpPWpGaD
Afatinib—ERBB4—Immune System—C3—amyotrophic lateral sclerosis	2.32e-05	0.000307	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	2.3e-05	0.000305	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.3e-05	0.000305	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	2.29e-05	0.000304	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—C3—amyotrophic lateral sclerosis	2.28e-05	0.000303	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	2.26e-05	0.0003	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	2.26e-05	0.000299	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.24e-05	0.000298	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.24e-05	0.000297	CbGpPWpGaD
Afatinib—BLK—Immune System—C3—amyotrophic lateral sclerosis	2.23e-05	0.000295	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.22e-05	0.000295	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.21e-05	0.000293	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	2.17e-05	0.000288	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.17e-05	0.000288	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.17e-05	0.000288	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.17e-05	0.000287	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.14e-05	0.000284	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.14e-05	0.000283	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	2.12e-05	0.000281	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.11e-05	0.000279	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.1e-05	0.000278	CbGpPWpGaD
Afatinib—ABL1—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.09e-05	0.000278	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.09e-05	0.000277	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.08e-05	0.000276	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.05e-05	0.000271	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	2.04e-05	0.000271	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.04e-05	0.00027	CbGpPWpGaD
Afatinib—EGFR—Disease—CST3—amyotrophic lateral sclerosis	2.03e-05	0.000269	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.03e-05	0.000269	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	2.03e-05	0.000269	CbGpPWpGaD
Afatinib—ERBB2—Disease—APOE—amyotrophic lateral sclerosis	2.02e-05	0.000268	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.01e-05	0.000267	CbGpPWpGaD
Afatinib—ERBB4—Disease—APOE—amyotrophic lateral sclerosis	1.99e-05	0.000264	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	1.99e-05	0.000264	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.98e-05	0.000263	CbGpPWpGaD
Afatinib—ABL1—Immune System—ATF1—amyotrophic lateral sclerosis	1.96e-05	0.00026	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.96e-05	0.000259	CbGpPWpGaD
Afatinib—LCK—Disease—CST3—amyotrophic lateral sclerosis	1.96e-05	0.000259	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	1.95e-05	0.000259	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—C3—amyotrophic lateral sclerosis	1.95e-05	0.000259	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.95e-05	0.000259	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.93e-05	0.000256	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD40LG—amyotrophic lateral sclerosis	1.92e-05	0.000255	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.92e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.91e-05	0.000253	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—C3—amyotrophic lateral sclerosis	1.88e-05	0.000249	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.88e-05	0.000249	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	1.87e-05	0.000249	CbGpPWpGaD
Afatinib—ABL1—Immune System—CASP9—amyotrophic lateral sclerosis	1.87e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.85e-05	0.000245	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.84e-05	0.000243	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.83e-05	0.000243	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	1.82e-05	0.000241	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—C3—amyotrophic lateral sclerosis	1.81e-05	0.000239	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.79e-05	0.000238	CbGpPWpGaD
Afatinib—EGFR—Immune System—SQSTM1—amyotrophic lateral sclerosis	1.79e-05	0.000237	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.77e-05	0.000235	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP9—amyotrophic lateral sclerosis	1.73e-05	0.00023	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.73e-05	0.000229	CbGpPWpGaD
Afatinib—LCK—Immune System—SQSTM1—amyotrophic lateral sclerosis	1.72e-05	0.000229	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.72e-05	0.000228	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.7e-05	0.000226	CbGpPWpGaD
Afatinib—IRAK1—Immune System—C3—amyotrophic lateral sclerosis	1.7e-05	0.000225	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.69e-05	0.000225	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.68e-05	0.000223	CbGpPWpGaD
Afatinib—EGFR—Immune System—ATF1—amyotrophic lateral sclerosis	1.68e-05	0.000223	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.64e-05	0.000218	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.62e-05	0.000215	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.62e-05	0.000215	CbGpPWpGaD
Afatinib—LCK—Immune System—ATF1—amyotrophic lateral sclerosis	1.62e-05	0.000214	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.61e-05	0.000213	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	1.6e-05	0.000212	CbGpPWpGaD
Afatinib—EGFR—Immune System—CASP9—amyotrophic lateral sclerosis	1.6e-05	0.000212	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—VEGFA—amyotrophic lateral sclerosis	1.56e-05	0.000206	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.55e-05	0.000205	CbGpPWpGaD
Afatinib—LCK—Immune System—CASP9—amyotrophic lateral sclerosis	1.54e-05	0.000204	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.52e-05	0.000202	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.52e-05	0.000202	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	1.51e-05	0.0002	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.5e-05	0.000199	CbGpPWpGaD
Afatinib—EGFR—Disease—CASP9—amyotrophic lateral sclerosis	1.48e-05	0.000196	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.45e-05	0.000192	CbGpPWpGaD
Afatinib—LCK—Disease—CASP9—amyotrophic lateral sclerosis	1.42e-05	0.000189	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.42e-05	0.000188	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.41e-05	0.000187	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.41e-05	0.000187	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.39e-05	0.000185	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—amyotrophic lateral sclerosis	1.39e-05	0.000184	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB4—amyotrophic lateral sclerosis	1.37e-05	0.000181	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—amyotrophic lateral sclerosis	1.36e-05	0.000181	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.34e-05	0.000178	CbGpPWpGaD
Afatinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	1.33e-05	0.000176	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.32e-05	0.000175	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	1.32e-05	0.000175	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.3e-05	0.000172	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD40LG—amyotrophic lateral sclerosis	1.29e-05	0.000171	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.27e-05	0.000169	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB4—amyotrophic lateral sclerosis	1.26e-05	0.000167	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.24e-05	0.000165	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.24e-05	0.000165	CbGpPWpGaD
Afatinib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	1.24e-05	0.000164	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.24e-05	0.000164	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.24e-05	0.000164	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	1.22e-05	0.000161	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.2e-05	0.000159	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.17e-05	0.000155	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.16e-05	0.000153	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.15e-05	0.000153	CbGpPWpGaD
Afatinib—EGFR—Immune System—C3—amyotrophic lateral sclerosis	1.14e-05	0.000151	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.12e-05	0.000148	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.11e-05	0.000147	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.1e-05	0.000146	CbGpPWpGaD
Afatinib—LCK—Immune System—C3—amyotrophic lateral sclerosis	1.1e-05	0.000145	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.09e-05	0.000144	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.05e-05	0.000139	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.05e-05	0.000139	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.03e-05	0.000137	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.02e-05	0.000136	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.02e-05	0.000135	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.01e-05	0.000134	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.96e-06	0.000132	CbGpPWpGaD
Afatinib—EGFR—Disease—APOE—amyotrophic lateral sclerosis	9.77e-06	0.00013	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	9.63e-06	0.000128	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—amyotrophic lateral sclerosis	9.42e-06	0.000125	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.29e-06	0.000123	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	9.06e-06	0.00012	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9e-06	0.000119	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.87e-06	0.000118	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.85e-06	0.000117	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.53e-06	0.000113	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.51e-06	0.000113	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.46e-06	0.000112	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.38e-06	0.000111	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.32e-06	0.00011	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.02e-06	0.000106	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	7.93e-06	0.000105	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	7.64e-06	0.000101	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.64e-06	0.000101	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.53e-06	9.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.35e-06	9.75e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.08e-06	9.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.84e-06	9.07e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—amyotrophic lateral sclerosis	6.7e-06	8.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.59e-06	8.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.51e-06	8.63e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	6.45e-06	8.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.15e-06	8.16e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.77e-06	7.65e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.69e-06	7.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.65e-06	7.5e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.52e-06	7.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.46e-06	7.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.45e-06	7.22e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.24e-06	6.94e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.02e-06	6.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.35e-06	5.77e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.19e-06	5.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.17e-06	5.53e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	4.13e-06	5.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.11e-06	5.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.96e-06	5.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.69e-06	4.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.56e-06	4.72e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.83e-06	3.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.79e-06	3.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.69e-06	3.57e-05	CbGpPWpGaD
